SAHPRA Updates Consolidated Schedules July 2026: South Africa

• The Minister of Health has updated the Consolidated Schedules on the recommendation of SAHPRA.
• The update was made under section 22A(2) and 37A of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965).
• The updated schedules will have far-reaching implications for stakeholders in the pharmaceutical sector.
• Compliance with the Medicines and Related Substances Act is crucial to avoid penalties and reputational damage.

The update was made under section 22A(2) and 37A of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965).

The Minister of Health has taken a significant step in updating the Consolidated Schedules, which are crucial for compliance with the Medicines and Related Substances Act. The update was made on the recommendation of SAHPRA, the regulatory authority responsible for ensuring the safety and efficacy of health products in South Africa. This development is particularly noteworthy as it highlights the ongoing efforts to refine and improve the regulatory framework governing the pharmaceutical industry in the country.

The Consolidated Schedules are a critical component of the Medicines and Related Substances Act, which outlines the guidelines and regulations for the registration, manufacture, and distribution of medicines in South Africa. The updated schedules will have far-reaching implications for stakeholders in the pharmaceutical sector, including manufacturers, distributors, and healthcare professionals.

The update is also significant because it underscores the Minister's powers under section 22A(2) and 37A of the Act. These provisions empower the Minister to make regulations and updates to the Schedules as necessary to ensure compliance with the Act.

The Medicines and Related Substances Act No. 101 of 1965 is a cornerstone legislation in South Africa's pharmaceutical regulatory framework. The Act sets out the guidelines and regulations for the registration, manufacture, and distribution of medicines in the country. SAHPRA plays a crucial role in ensuring compliance with the Act by regulating the safety and efficacy of health products.

The update to the Consolidated Schedules is a testament to the ongoing efforts to refine and improve the regulatory framework governing the pharmaceutical industry in South Africa. The legislation provides a robust framework for ensuring the quality, safety, and efficacy of medicines, which is critical for protecting public health.

Section 22A(2) and 37A of the Act grant the Minister significant powers to make regulations and updates to the Schedules as necessary to ensure compliance with the Act. This provision underscores the importance of regular updates to the Consolidated Schedules in maintaining a robust regulatory framework.

The updated Consolidated Schedules have significant implications for stakeholders in the pharmaceutical sector, including manufacturers, distributors, and healthcare professionals. Compliance with the Medicines and Related Substances Act is crucial to avoid penalties and reputational damage.

Lawyers should pay close attention to the updated Schedules as they may impact compliance with the Act, particularly in relation to the Minister's powers under section 22A(2) and 37A. The update highlights the ongoing efforts to refine and improve the regulatory framework governing the pharmaceutical industry in South Africa.

The development also underscores the importance of regular updates to the Consolidated Schedules in maintaining a robust regulatory framework that ensures public health is protected.

Lawyers should watch for the updated Schedules, which may impact compliance with the Medicines and Related Substances Act, particularly in relation to the Minister's powers under section 22A(2) and 37A.

Source: Original reporting via [Source title]